The Medicines Company expands into Russian pharmaceutical market
US drugmaker The Medicines Company (Nasdaq: MDCO) is expanding into Russia, through the start of sales of its drugs in the local market via the local Rayfarm consulting company.
Under the terms of the agreement between the partners, Rayfarm will focus on the promotion of MDC’s drugs in Russia and the search for distributors. There is also a possibility that Rayfarm will deal with the registration of MDC drugs in Russia, as well as their marketing and sales.
MDC specializes in the development of drugs and technologies to help patients in emergency situations and in partucular intensive treatment units. In 2011 the company’s turnover amounted to $484,7 million, while net income was $127.88 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze